Sobi and Apellis announce first patient dosed in potentially registrational ALS study of pegcetacoplan
· 52-week phase 2 MERIDIAN study to evaluate pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with ALS Stockholm, Sweden and Waltham MA, USA - Swedish Orphan Biovitrum AB (publ) (Sobi[TM]) (STO:SOBI) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the first patient has been dosed in the potentially registrational phase 2 MERIDIAN study of pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with sporadic amyotrophic lateral sclerosis (ALS). Studies suggest that elevated levels of C3